Community-Acquired and Nosocomial Pneumonia: Clinical and Morphological Features

Голубев, А. М; Смелая, Т. В.; Мороз, В. В; Попов, А. А.; Толбатов, А. А.; Медунецкая, С. В.

doi:10.15360/1813-9779-2010-3-5

Cited by 6 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…spp., Burkholderia spp., Stenotrophomonas spp., облада ют способностью формировать биопленки, что за щищает их от действия иммунной системы и анти биотиков [1][2][3][4].…”

unclassified

Inhaled Tobramycin in the Treatment of Severe Nosocomial Pneumonias

Мороз¹,

Kuzovlev²,

Половников³

et al. 2012

rmt

Self Cite

View full text Add to dashboard Cite

unclassified

Inhaled Tobramycin in the Treatment of Severe Nosocomial Pneumonias

Мороз¹,

Kuzovlev²,

Половников³

et al. 2012

rmt

Self Cite

View full text Add to dashboard Cite

“…Pseudomonas aeruginosa, Acinetobacter spp., Burkholderia spp., Stenotrophomonas spp. present with a property to form biofilms which protect them against antibiotics and immune cells [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Use of Inhaled Tobramycin for the Treatment of Severe Nosocomia Pneumonia

An¹

2012

J Pulmon Resp Med

View full text Add to dashboard Cite

Objective:The objective of the study was to estimate the efficacy and safety of Inhaled Tobramycin (IT) as an adjunct to systemic antibiotics in the treatment of severe Nosocomial Pneumonia (NP).Patients and methods: 25 mechanically ventilated patients (out of 165 screened) were enrolled in the current observational single-center study. They were randomized to receive either IT (300mg, BID; group 1, n=15) as an adjunct to systemic antibiotics or for a correction of the regimen of systemic antibiotics (group 2, n=10). The primary outcome measure was resolution of NP and acute respiratory insufficiency. The CPIS, signs of Systemic Inflammatory Response Syndrome (SIRS) and oxygenation index were used as objective indicators of the clinical progress. Results:The following signs of IT efficacy were detected in 87% of group 1 patients: a decrease of SIRS and CPIS scores within 2, 3 ± 1, 2 days of IT therapy (p<0,05); decrease of microbes titer to 10 3 -10 4 CFU/ml (p<0,05); increase of microbes sensitivity to systemic antibiotics in 40% of patients; positive X-ray dynamics in 60% of patients within 9, 0 ± 2, 5 days of IT therapy. No serious side effects of IT were observed. Conclusion:Administration of IT as an adjunct to systemic antibiotics is efficient and safe in 87% of patients with severe NP caused by multi resistant gram-negative bacteria.

show abstract

“…Pseudomonas aeruginosa, Acinetobacter spp., Burkholderia spp., Stenotrophomonas spp., have a natural property to form biolayers, which protect them against the immune system and antibiotics. There are currently no perspectives of producing new classes of antibiotics [2,3]. In view of the abovementioned special regimens of antibiotic therapy are recommended: increase of doses, continuous infusions, etc.…”

mentioning

confidence: 99%

Inhaled Tobramycin in the Treatment of Nosocomial Pneumonia in Severe Sepsis

An¹

2014

J Pulm Respir Med

View full text Add to dashboard Cite

Community-Acquired and Nosocomial Pneumonia: Clinical and Morphological Features

Cited by 6 publications

References 3 publications

Inhaled Tobramycin in the Treatment of Severe Nosocomial Pneumonias

Inhaled Tobramycin in the Treatment of Severe Nosocomial Pneumonias

Use of Inhaled Tobramycin for the Treatment of Severe Nosocomia Pneumonia

Inhaled Tobramycin in the Treatment of Nosocomial Pneumonia in Severe Sepsis

Contact Info

Product

Resources

About